Skip to main content

Nonoperative Management of Rectovaginal Fistula

Nonoperative management of rectovaginal fistula (RVF) encompasses conservative local wound care, draining-seton placement, medical therapy for Crohn's disease, and fecal diversion. Per the ASCRS Clinical Practice Guidelines (2022), nonoperative management is typically the initial care for obstetric RVF and may also be considered for other benign, minimally symptomatic fistulae, with spontaneous-healing rates of 52–66% over 3–6 months (Recommendation 12, Grade 2C).[2] A draining seton (Recommendation 13, Grade 1C) is the workhorse adjunct that resolves acute inflammation and infection while a definitive plan is built.[2] For Crohn's RVF, the AGA and ACG 2025 position medical therapy with anti-TNF ± immunomodulator + seton drainage as the cornerstone of initial care, with surgery deferred until endoscopic mucosal healing of the rectosigmoid is confirmed.[1][6][7]

For the surgical procedure of choice once the fistula is ready for definitive repair, see ERAF ± Sphincteroplasty. For broader context see Rectovaginal Fistula.

1 — Conservative Local Wound Care​

First-line for most obstetric RVF and select benign fistulae. Goal: resolve acute inflammation and infection, allow spontaneous closure.[2]

ComponentNotes
Sitz bathsWarm-water soaks for perineal hygiene and comfort
Local wound careGentle cleansing; keep perineum clean and dry
DebridementAs needed for necrotic tissue at the fistula site
AntibioticsOnly when clinical infection is present (cellulitis, abscess, purulent drainage); not routine[2]
Stool-bulking fiberFormed soft stools minimize mechanical trauma to the tract[2]
Stool softenersAvoid straining and reduce septal pressure

Duration: typically 3–6 months before reassessing for spontaneous closure.[2]

Healing rate: 52–66% for obstetric RVF (Homsi meta-analysis, Oakley, Lo).[2] Benign minimally symptomatic non-obstetric RVF may also heal nonoperatively, but follow-up data are limited.

Best candidates: small low obstetric RVF, acute / early presentation, minimal symptoms, no sphincter defect, no active Crohn's or radiation injury.

2 — Draining Seton​

ASCRS Recommendation 13 (Grade 1C): a draining seton facilitates resolution of acute inflammation or infection associated with RVF.[2] Seton placement is procedural but counted within the nonoperative / preparatory pathway rather than definitive repair.

Indications:

  • Narrow tract with small vaginal opening (abscess risk if drainage impeded)[2]
  • Multiple tracts[2]
  • Active inflammatory or neoplastic process requiring further treatment before definitive repair[2]
  • Poor candidates for definitive repair — long-term symptomatic relief[2]
  • Bridge to definitive repair — relieves edema / inflammation / infection, improving subsequent flap success[2]

Technique: multidisciplinary EUA — probe and curette the tract, thread a vessel loop or silastic seton from rectal to vaginal opening and tie loosely. Curettage during placement may itself promote secondary-intention closure.[3]

Outcome: prior seton independently predicts higher success of subsequent definitive repair (Sonoda 2002 — P = 0.025).[4] Setons rarely close the fistula on their own.

3 — Medical Therapy for Crohn's-Related RVF​

Crohn's RVF is the one setting where medical therapy is the cornerstone. The goal is endoscopic healing of the rectal mucosa before any operative repair is attempted.[1][5][6]

Antibiotics​

  • Metronidazole 10–20 mg/kg/day PO × 4–8 wk, and/or ciprofloxacin 500 mg PO BID × 4–8 wk, or levofloxacin 500–750 mg daily × 4–8 wk[6]
  • Adjunctive role for pelvic sepsis around complex fistulas; do not replace surgical drainage when an abscess is present[6]
  • AGA recommends against antibiotics alone for induction of fistula remission (conditional, low certainty)[7]
  • High relapse rate after stopping; combine with biologic or surgery[1]
  • Combination therapy — ciprofloxacin + infliximab or ciprofloxacin + adalimumab outperforms anti-TNF monotherapy[5]

Anti-TNF therapy​

Infliximab is the only anti-TNF agent with a dedicated RCT (ACCENT II) for perianal-fistula closure and is the first-line biologic for Crohn's RVF.[5][6][7]

PhaseRegimen
Induction5 mg/kg at weeks 0, 2, and 6 — produces complete cessation of perianal-fistula drainage in most patients[6]
Maintenance5 mg/kg every 8 weeks — maintains complete closure / response[6]

ACCENT II: scheduled q-8-week infliximab significantly prolonged fistula closure vs placebo — median time to loss of response > 40 weeks vs 14 weeks for placebo.[8] Subgroup data support efficacy in rectovaginal-fistula maintenance specifically.[5][6]

AGA strongly recommends infliximab over no treatment for induction and maintenance of fistula remission (strong, moderate certainty).[7]

Other biologics:

AgentAGA positionNotes
AdalimumabSuggested over no treatment (conditional, low certainty)No dedicated fistula-primary-endpoint RCT[5][7]
Ustekinumab, vedolizumabSuggested over no treatment (conditional, low certainty) for induction or maintenance[7]
Certolizumab pegolEvidence suggests may not be effective for induction of fistula remission[7]

Immunomodulators​

  • Azathioprine / 6-mercaptopurine — guideline-recommended for complex fistulas; slow onset, more useful for maintaining closure than induction[1][5]
  • ACG 2025 recommends infliximab + immunomodulator as the initial combination for Crohn's RVF before surgery[6]

Seton + biologic combination​

Seton placement followed by infliximab consistently yields:[5][6]

  • Better overall fistula-healing response
  • Longer duration of closure
  • Prevention of recurrent abscess
  • Lower overall recurrence

Systematic review + meta-analysis (10 studies, 4 RCTs) — anti-TNF + temporary seton likely beneficial; subgroup of trials with follow-up > 4 wk: complete healing 46% vs 13% (P = 0.003).[2]

Calcineurin inhibitors (last resort)​

  • Tacrolimus — single short-term placebo-controlled trial showed reduction in draining fistulas; nephrotoxicity and other side effects frequent[1]
  • Cyclosporine — uncontrolled case series only; significant toxicity[1]
  • Reserved for selected patients failing multimodality treatment[1]

4 — Fecal Diversion Alone​

Diverting loop ileostomy or colostomy without definitive fistula repair has three roles:[2][9]

  • ASCRS recommends fecal diversion as the initial step for RVFs from colorectal anastomotic complications — facilitates resolution of acute inflammation.[2]
  • Healing with diversion alone: ~37% (6/16 in one anastomotic-RVF series).[2]

Bridge to definitive repair​

  • Reduces fecal contamination of the tract; tissue quality improves before definitive repair.
  • In refractory Crohn's, proximal diversion may permit rectal / perianal healing — long-term success of diverting ostomy for perianal CD remains low overall.[6]

Palliation​

  • Symptomatic relief for poor surgical candidates / those declining repair.
  • For radiation RVF, proctectomy + diverting stoma yields significantly better quality of life than stoma alone (less tenesmus and anal discharge at 6 and 12 mo).[2]

Diversion as adjunct to repair​

Obi 2026 (n = 158): multiple prior failed repairs and interposition flap use predicted use of fecal diversion. Cumulative 5-yr cure: 72.7% diverted vs 64.3% non-diverted (P = 0.38) — selecting high-risk patients for diversion appears to equalize recurrence with lower-risk non-diverted patients.[9]

5 — Fibrin Glue and Fistula Plug — Not Recommended​

ASCRS does not include fibrin glue or anal-fistula plug in the RVF guidelines because success has been prohibitively poor for RVF.[2]

ModalityReported successNotes
Fibrin glue18–41% (anal fistulas overall); 31–67% in Crohn's-specific dataHistorical small series of 5 RVF showed 60% but contemporary data disappointing[2][10][11]
Anal-fistula plug≤ 50%; early failure 4–41%Failure more common in Crohn's, anovaginal, and recurrent fistulas; no benefit over seton removal alone in Crohn's[2][11]

6 — Emerging and Adjunctive Therapies​

Vaginal estrogen:

  • Proposed adjunct for poorly healing RVF in postmenopausal women / vaginal atrophy.[12][13]
  • Case report: pessary-induced RVF closed with vaginal estradiol cream within one month.[13]
  • Animal data — postoperative vaginal estrogen promotes epithelial healing but adversely affects stromal layer (decreased stiffness, decreased collagen).[14]
  • Not yet routinely recommended.[12]

Microbiome modulation: vaginal and rectal microbiome may influence fistula healing; antibiotic prophylaxis targeting pathogenic organisms and microbiome research are active investigation areas.[12]

Algorithm by etiology​

EtiologyFirst-line nonoperative approachHealing rateDurationKey consideration
ObstetricSitz baths, wound care, fiber, antibiotics PRN52–66%3–6 moMost likely to heal spontaneously; seton if abscess risk[2]
Crohn's diseaseSeton + infliximab ± immunomodulator; antibiotics adjunctive46% (seton + anti-TNF)Until endoscopic mucosal healingMust achieve endoscopic remission before surgery[1][5][6]
AnastomoticFecal diversion~37%VariableInitial step; persistent fistula needs surgery[2]
RadiationFecal diversion ± medical optimizationLowVariablePoor tissue quality; proctectomy often ultimately needed[2]
Minimally symptomatic / benignConservative wound careLimited data3–6 moSurgery if persistent[2]

When to transition to operative management​

Abandon nonoperative management and proceed to surgical repair when:[1][2]

  • Fistula persists after 3–6 months of conservative therapy
  • Symptoms are disabling (significant stool / flatus per vagina, recurrent infection)
  • In Crohn's: fistula persists after medical therapy has achieved endoscopic healing of the rectosigmoid with no anorectal stricture or active rectal disease
  • Abscess develops that cannot be controlled with seton drainage
  • Concern for malignancy at the fistula site

References​

1. American Gastroenterological Association. "Medical position statement: perianal Crohn's disease." Gastroenterology. 2003;125(5):1503–1507. doi:10.1016/j.gastro.2003.08.024

2. Gaertner WB, Burgess PL, Davids JS, et al. "The American Society of Colon and Rectal Surgeons clinical practice guidelines for the management of anorectal abscess, fistula-in-ano, and rectovaginal fistula." Dis Colon Rectum. 2022;65(8):964–985. doi:10.1097/DCR.0000000000002473

3. Muñoz JM, Levin PJ, Saur NM, Cox CK. "Multidisciplinary approach to evaluation of rectovaginal fistulas." Am J Obstet Gynecol. 2024;231(2):285–286. doi:10.1016/j.ajog.2024.04.029

4. Sonoda T, Hull T, Piedmonte MR, Fazio VW. "Outcomes of primary repair of anorectal and rectovaginal fistulas using the endorectal advancement flap." Dis Colon Rectum. 2002;45(12):1622–1628. doi:10.1007/s10350-004-7249-y

5. Lichtenstein GR, Loftus EV, Isaacs KL, et al. "ACG clinical guideline: management of Crohn's disease in adults." Am J Gastroenterol. 2018;113(4):481–517. doi:10.1038/ajg.2018.27

6. Lichtenstein GR, Loftus EV, Afzali A, et al. "ACG clinical guideline: management of Crohn's disease in adults." Am J Gastroenterol. 2025;120(6):1225–1264. doi:10.14309/ajg.0000000000003465

7. Feuerstein JD, Ho EY, Shmidt E, et al. "AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn's disease." Gastroenterology. 2021;160(7):2496–2508. doi:10.1053/j.gastro.2021.04.022

8. Sands BE, Anderson FH, Bernstein CN, et al. "Infliximab maintenance therapy for fistulizing Crohn's disease." N Engl J Med. 2004;350(9):876–885. doi:10.1056/NEJMoa030815

9. Obi M, Kanters A, Spivak AR, et al. "Factors associated with fecal diversion prior to rectovaginal fistula repair." J Gastrointest Surg. 2026:102442. doi:10.1016/j.gassur.2026.102442

10. Abel ME, Chiu YS, Russell TR, Volpe PA. "Autologous fibrin glue in the treatment of rectovaginal and complex fistulas." Dis Colon Rectum. 1993;36(5):447–449. doi:10.1007/BF02050009

11. Aaron AE, Amabile A, Andolfi C, et al. Gastrointestinal Surgical Emergencies Textbook. American College of Surgeons; 2021.

12. Satora M, Żak K, Frankowska K, et al. "Perioperative factors affecting the healing of rectovaginal fistula." J Clin Med. 2023;12(19):6421. doi:10.3390/jcm12196421

13. Cichowski S, Rogers RG. "Nonsurgical management of a rectovaginal fistula caused by a Gellhorn pessary." Obstet Gynecol. 2013;122(2 Pt 2):446–449. doi:10.1097/AOG.0b013e31828aec98

14. Ripperda CM, Maldonado PA, Acevedo JF, et al. "Vaginal estrogen: a dual-edged sword in postoperative healing of the vaginal wall." Menopause. 2017;24(7):838–849. doi:10.1097/GME.0000000000000840